A61K 39/02
Bacterial antigens
A61K39/02 (Bacterial antigens) appears on 5,148 US grants and 7,117 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,148
- Published applications
- 7,117
- Assignees
- 2,450
- Inventors
- 10,114
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 13 | 0 |
| 1978 | 13 | 0 |
| 1979 | 17 | 0 |
| 1980 | 28 | 0 |
| 1981 | 21 | 0 |
| 1982 | 22 | 0 |
| 1983 | 16 | 0 |
| 1984 | 21 | 0 |
| 1985 | 12 | 0 |
| 1986 | 12 | 0 |
| 1987 | 20 | 0 |
| 1988 | 32 | 0 |
| 1989 | 15 | 0 |
| 1990 | 8 | 0 |
| 1991 | 18 | 0 |
| 1992 | 17 | 0 |
| 1993 | 20 | 0 |
| 1994 | 20 | 0 |
| 1995 | 23 | 0 |
| 1996 | 30 | 0 |
| 1997 | 46 | 0 |
| 1998 | 74 | 0 |
| 1999 | 83 | 0 |
| 2000 | 56 | 0 |
| 2001 | 67 | 28 |
| 2002 | 76 | 124 |
| 2003 | 72 | 139 |
| 2004 | 66 | 179 |
| 2005 | 77 | 168 |
| 2006 | 91 | 206 |
| 2007 | 64 | 238 |
| 2008 | 81 | 245 |
| 2009 | 100 | 253 |
| 2010 | 148 | 301 |
| 2011 | 144 | 316 |
| 2012 | 170 | 303 |
| 2013 | 184 | 327 |
| 2014 | 244 | 375 |
| 2015 | 277 | 419 |
| 2016 | 310 | 399 |
| 2017 | 311 | 403 |
| 2018 | 290 | 353 |
| 2019 | 279 | 335 |
| 2020 | 302 | 371 |
| 2021 | 275 | 342 |
| 2022 | 206 | 312 |
| 2023 | 192 | 274 |
| 2024 | 186 | 299 |
| 2025 | 186 | 231 |
| 2026 | 102 | 177 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 39/025Enterobacteriales951
- A61K 39/09Lactobacillales907
- A61K 39/04Mycobacterium614
- A61K 39/08Clostridium553
- A61K 39/095Neisseria520
- A61K 39/102Pasteurellales446
- A61K 39/085Staphylococcus385
- A61K 39/0208Specific bacteria not otherwise provided for268
All 23 subgroupsShow fewer
- A61K 39/099Bordetella232
- A61K 39/05Actinobacteria212
- A61K 39/07Bacillus207
- A61K 39/104Pseudomonadales187
- A61K 39/0225Spirochetes186
- A61K 39/105Delta proteobacteriales177
- A61K 39/0241Mollicutes160
- A61K 39/107Vibrio146
- A61K 39/0233Rickettsiales99
- A61K 39/116Polyvalent bacterial antigens99
- A61K 39/0216Bacteriodetes80
- A61K 39/098Brucella37
- A61K 39/114Fusobacterium26
- A61K 2039/10BrucellaIndexing code11
- A61K 2039/106VibrioIndexing code5
Recent patents
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Immunomodulatory and oncolytic minicells and methods of use22 Sep 2026US 12,741,010 B2Vaxiion Therapeutics, Inc.
- Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect15 Sep 2026US 12,734,226 B2Revance Therapeutics, Inc.
- Staphylococcus aureus vaccine compositions15 Sep 2026US 12,734,227 B2New York University
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
Most cited
By later US patents
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Methods for treating HIV infected subjects339US 7,232,566 B2Genetics Institute, Inc. · 2007
- Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery242US 6,060,082 AMassachusetts Institute of Technology · 2000